BioMarin Pharmaceutical (BMRN) reported Q1 non-GAAP earnings late Thursday of $1.13 per diluted share, up from $0.71 a year earlier.
Analysts polled by FactSet expected $0.95.
Revenue in the three months ended March 31 rose to $745.1 million from $648.8 million a year earlier.
Analysts surveyed by FactSet expected $738.7 million.
The company reiterated 2025 non-GAAP diluted EPS guidance of $4.20 to $4.40, on revenue of $3.1 billion to $3.2 billion. Analysts polled by FactSet expect EPS of $4.30 on revenue of $3.14 billion.
Shares of BioMarin rose 1.1% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.